Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CRL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| James Foster | $1,545,636 | $0 | $11,601,089 | $0 | $2,182,666 | $0 | $105,829 | $15,435,220 |
| Chair, President and Chief Executive Officer | ||||||||
| Birgit Girshick | 760,960 | 0 | 4,123,624 | 0 | 861,800 | 0 | 152,008 | 5,898,392 |
| Corporate Executive Vice President, Chief Operating Officer | ||||||||
| Joseph LaPlume | 570,167 | 0 | 2,260,459 | 0 | 563,612 | 0 | 119,107 | 3,513,345 |
| Corporate Executive Vice President, Corporate Development & Strategy | ||||||||
| Victoria Creamer | 553,753 | 0 | 2,106,458 | 0 | 547,386 | 0 | 124,790 | 3,332,387 |
| Corporate Executive Vice President and Chief People Officer | ||||||||
| Michael Knell | 448,118 | 30,000 | 1,195,459 | 0 | 347,500 | 0 | 86,607 | 2,107,684 |
| Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| James Foster | $15,435,220 | — | $14,096,924 | — |
| Birgit Girshick | 5,898,392 | — | 4,989,672 | — |
| Joseph LaPlume | 3,513,345 | — | 3,058,456 | — |
| Victoria Creamer | 3,332,387 | — | — | — |
| Michael Knell | 2,107,684 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 2026-05-01 | A | 21,112 | $166 | $3,499,947 | Common | Form 4 ↗ |
| Steven Barg | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Reshema Kemps-Polanco | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Craig B. Thompson | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Paul Graves | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Nancy C. Andrews | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| George Llado, Sr | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-05-08 | A | 422 | 178 | 74,956 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Virginia M. Wilson | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Reshema Kemps-Polanco | Director | 2026-05-08 | A | 535 | 178 | 95,027 | Common | Form 4 ↗ |
| Mark Enyedy | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| Martin Mackay | Director | 2026-05-08 | A | 1,438 | 178 | 255,418 | Common | Form 4 ↗ |
| George Llado, Sr | Director | 2026-05-08 | A | 450 | 178 | 79,929 | Common | Form 4 ↗ |
| Martin Mackay | Director | 2026-05-08 | A | 1,407 | 178 | 249,911 | Common | Form 4 ↗ |
| Nancy C. Andrews | Director | 2026-05-12 | D | 3,964 | 0 | 0 | Common | Form 4 ↗ |
| Nancy C. Andrews | Director | 2026-05-12 | A | 3,964 | 0 | 0 | Common | Form 4 ↗ |
| Michael Knell | SVP, Finance and CAO | 2026-05-26 | D | 50 | 160 | 8,015 | Common | Form 4 ↗ |
| Victoria Creamer | EVP & Chief People Officer | 2026-05-26 | D | 198 | 160 | 31,739 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-05-26 | D | 376 | 160 | 60,273 | Common | Form 4 ↗ |
| Victoria Creamer | EVP & Chief People Officer | 2026-05-26 | D | 148 | 157 | 23,196 | Common | Form 4 ↗ |
| Mark Mintz | EVP, Chief Information Officer | 2026-05-26 | D | 64 | 160 | 10,259 | Common | Form 4 ↗ |
| Mark Mintz | EVP, Chief Information Officer | 2026-05-26 | D | 47 | 157 | 7,366 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-05-26 | D | 242 | 157 | 37,929 | Common | Form 4 ↗ |
| Joseph LaPlume | EVP, Corp Strategy & Develop | 2026-05-26 | D | 243 | 160 | 38,953 | Common | Form 4 ↗ |
| Joseph LaPlume | EVP, Corp Strategy & Develop | 2026-05-26 | D | 185 | 157 | 28,995 | Common | Form 4 ↗ |
| Michael Knell | SVP, Finance and CAO | 2026-05-26 | D | 37 | 157 | 5,799 | Common | Form 4 ↗ |
| Joseph LaPlume | EVP, Corp Strategy & Develop | 2026-05-29 | A | 5,257 | 181 | 949,992 | Common | Form 4 ↗ |
| Mark Mintz | EVP, Chief Information Officer | 2026-05-29 | D | 64 | 181 | 11,565 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-05-29 | A | 9,961 | 181 | 1,800,052 | Common | Form 4 ↗ |
| Glenn Coleman | EVP & Chief Financial Officer | 2026-05-29 | A | 6,640 | 181 | 1,199,914 | Common | Form 4 ↗ |
| Mark Mintz | EVP, Chief Information Officer | 2026-05-29 | A | 2,534 | 181 | 457,919 | Common | Form 4 ↗ |
| Michael Knell | SVP, Finance and CAO | 2026-05-29 | A | 1,837 | 181 | 331,964 | Common | Form 4 ↗ |
| Michael Knell | SVP, Finance and CAO | 2026-05-29 | D | 152 | 181 | 27,468 | Common | Form 4 ↗ |
| Michael Knell | SVP, Finance and CAO | 2026-05-29 | D | 48 | 181 | 8,674 | Common | Form 4 ↗ |
| Victoria Creamer | EVP & Chief People Officer | 2026-05-29 | D | 616 | 181 | 111,317 | Common | Form 4 ↗ |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | 2026-05-29 | A | 4,361 | 181 | 788,076 | Common | Form 4 ↗ |
| Joseph LaPlume | EVP, Corp Strategy & Develop | 2026-05-29 | D | 235 | 181 | 42,467 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-05-29 | D | 1,204 | 181 | 217,575 | Common | Form 4 ↗ |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | 2026-05-29 | D | 170 | 181 | 30,721 | Common | Form 4 ↗ |
| Victoria Creamer | EVP & Chief People Officer | 2026-05-29 | A | 5,135 | 181 | 927,946 | Common | Form 4 ↗ |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | 2026-05-29 | D | 551 | 181 | 99,571 | Common | Form 4 ↗ |
| Mark Mintz | EVP, Chief Information Officer | 2026-05-29 | D | 305 | 181 | 55,117 | Common | Form 4 ↗ |
| Victoria Creamer | EVP & Chief People Officer | 2026-05-29 | D | 194 | 181 | 35,058 | Common | Form 4 ↗ |
| Joseph LaPlume | EVP, Corp Strategy & Develop | 2026-05-29 | D | 744 | 181 | 134,448 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-05-29 | D | 378 | 181 | 68,308 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-05-30 | D | 1,596 | 181 | 288,413 | Common | Form 4 ↗ |
| Steven Barg | Director | 2026-06-02 | A | 422 | 175 | 73,761 | Common | Form 4 ↗ |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | 2026-06-05 | D | 1,529 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | A | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-06-05 | D | 3,386 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | D | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | D | 153,361 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | A | 153,361 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-05 | D | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Birgit Girshick | Chief Executive Officer | 2026-06-05 | A | 3,386 | 0 | 0 | Common | Form 4 ↗ |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | 2026-06-05 | A | 1,529 | 0 | 0 | Common | Form 4 ↗ |
| James C. Foster | Director | 2026-06-29 | D | 75,000 | 225 | 16,875,000 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joseph LaPlume | PSU | 2025-02-11 | — | — | 6,709 | — | $909,942 |
| Birgit Girshick | PSU | 2025-02-11 | 6,108 | 18,795 | — | 37,590 | 2,463,649 |
| Victoria Creamer | RSU | 2025-02-11 | — | 39,380 | — | 393,803 | 787,606 |
| James Foster | PSU | 2025-02-11 | 22,962 | 70,652 | — | 141,304 | 9,261,064 |
| Michael Knell | PSU | 2025-02-11 | 1,030 | 1,030 | — | — | 415,524 |
| Joseph LaPlume | PSU | 2025-02-11 | 3,348 | 10,303 | — | 20,606 | 1,350,517 |
| James Foster | PSU | 2025-02-11 | — | — | 17,253 | — | 2,340,024 |
| Joseph LaPlume | RSU | 2025-02-11 | — | 40,548 | — | 405,476 | 810,952 |
| Michael Knell | RSU | 2025-09-19 | — | 2,926 | — | — | 499,995 |
| Birgit Girshick | PSU | 2025-02-11 | — | — | 12,239 | — | 1,659,976 |
| Michael Knell | RSU | 2025-02-11 | — | 2,064 | — | — | 279,940 |
| Birgit Girshick | RSU | 2025-02-11 | — | 62,000 | — | 620,000 | 1,240,000 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Joseph LaPlume | $810,952 | $2,260,459 | $0 | 73.6% |
| Birgit Girshick | 1,240,000 | 4,123,625 | 0 | 76.9% |
| Victoria Creamer | 787,606 | 0 | 0 | 0.0% |
| James Foster | 0 | 11,601,088 | 0 | 100.0% |
| Michael Knell | 779,935 | 415,524 | 0 | 34.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Victoria Creamer | Option | 3,110 | 337.99 | — |
| Joseph LaPlume | Option | 3,476 | 337.99 | — |
| Birgit Girshick | Option | 3,659 | 337.99 | — |
| James Foster | Option | 6,011 | 244.41 | — |
| Joseph LaPlume | PSU | 26,660 | — | 5,429,576 |
| Victoria Creamer | RSU | 9,107 | — | 1,854,732 |
| Michael Knell | Option | 1,006 | 337.99 | — |
| Birgit Girshick | Option | 6,500 | 179.66 | — |
| Birgit Girshick | Option | 4,573 | 194.12 | — |
| Birgit Girshick | Option | 6,542 | 208.44 | — |
| Joseph LaPlume | Option | 6,685 | 179.66 | — |
| Joseph LaPlume | Option | 1,120 | 244.41 | — |
| Victoria Creamer | Option | 4,179 | 179.66 | — |
| Victoria Creamer | Option | 2,410 | 194.12 | — |
| Pease | Option | 4,649 | 245.88 | — |
| Pease | Option | 3,317 | 244.41 | — |
| Victoria Creamer | Option | 1,009 | 244.41 | — |
| Birgit Girshick | PSU | 48,598 | — | 9,897,469 |
| Birgit Girshick | RSU | 17,638 | — | 3,592,155 |
| James Foster | RSU | 17,253 | — | 3,513,746 |
| Joseph LaPlume | RSU | 16,574 | — | 3,375,461 |
| Michael Knell | RSU | 6,698 | — | 1,364,115 |
| James Foster | PSU | 183,136 | — | 37,297,478 |
| Victoria Creamer | PSU | 24,843 | — | 5,059,525 |
| Michael Knell | PSU | 8,197 | — | 1,669,401 |
| James Foster | Option | 28,733 | 179.66 | — |
| James Foster | Option | 18,869 | 337.99 | — |
| James Foster | Option | 14,088 | 194.12 | — |
| James Foster | Option | 18,644 | 208.44 | — |
| Birgit Girshick | Option | 1,659 | 244.41 | — |
| Joseph LaPlume | Option | 2,626 | 194.12 | — |
| Joseph LaPlume | Option | 3,598 | 208.44 | — |
| Victoria Creamer | Option | 3,353 | 208.44 | — |
| Pease | Option | 1,226 | 208.44 | — |
The purpose of our compensation program is to motivate, recruit and retain the strongest possible management team, and simultaneously align management s interest with those of our shareholders. Our philosophy behind the Compensation Program is that it should appropriately align executive compensation with both the short- and long-term performance of the Company and our commitment to our shareholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-05 | 41,356,139 | 2,716,251 | 30,305 | 93.84% | Passed |
| 2025 | 2025-05-20 | 40,218,870 | 1,432,240 | 102,252 | 96.56% | Passed |
| 2024 | 2024-05-08 | 43,833,503 | 2,299,362 | 55,335 | 95.02% | Passed |
| 2023 | 2023-05-09 | 40,252,161 | 5,727,678 | 31,338 | 87.54% | Passed |
| 2022 | 2022-05-10 | 39,792,720 | 5,179,352 | 24,446 | 88.48% | Passed |
| 2021 | 2021-05-06 | 38,268,849 | 6,446,976 | 27,518 | 85.58% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-05 | 93.84%a |
| 2025 | 2025-05-20 | 96.56%b |
| 2024 | 2024-05-08 | 95.02%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Broker non-votes (if applicable) and abstentions will have no effect on the voting on any matter that requires the affirmative vote of a majority of the votes cast on the matter.”.
c. Approved under the standard stated in the filing — “Broker non-votes (if applicable) and abstentions will have no effect on the voting on any matter that requires the affirmative vote of a majority of the votes cast on the matter.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 251 : 1 |
|---|---|
| CEO total compensation | $15,435,220 |
| Median employee compensation | $61,430 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Martin MackayIndependent · Board Chair · Lead Independent Director | $110,000 | $127,691 | $128,168 | $0 | $0 | $365,859 |
| Virginia M. WilsonIndependent | 90,000 | 127,691 | 128,168 | 0 | 0 | 345,859 |
| Paul GravesIndependent · Newly elected | 90,000 | 127,748 | 127,960 | 0 | 0 | 345,708 |
| Reshema Kemps-PolancoIndependent · Compensation (Chair) | 85,000 | 127,691 | 128,168 | 0 | 0 | 340,859 |
| Nancy C. AndrewsIndependent | 85,000 | 127,691 | 128,168 | 0 | 0 | 340,859 |
| Craig B. ThompsonIndependent · Compensation | 85,000 | 127,691 | 128,168 | 0 | 0 | 340,859 |
| George Llado, SrIndependent | 70,000 | 127,691 | 128,168 | 0 | 0 | 325,859 |
| Mark EnyedyIndependent · Newly elected | 65,000 | 127,748 | 127,960 | 0 | 0 | 320,708 |
| Abraham CeesayNot independent · Newly elected | 65,000 | 127,748 | 127,960 | 0 | 0 | 320,708 |
| Steven BargIndependent · Compensation · Newly elected | 65,000 | 127,748 | 127,960 | 0 | 0 | 320,708 |
| George E. MassaroIndependent · Not standing for re-election · Departed during FY | 28,750 | 0 | 0 | 0 | 0 | 28,750 |
| Richard F. WallmanIndependent · Not standing for re-election · Departed during FY | 26,250 | 0 | 0 | 0 | 0 | 26,250 |
| Robert BertoliniIndependent · Not standing for re-election · Departed during FY | 22,500 | 0 | 0 | 0 | 0 | 22,500 |
| Deborah T. KochevarIndependent · Not standing for re-election · Departed during FY | 21,250 | 0 | 0 | 0 | 0 | 21,250 |
| James C. FosterEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $65,000 |
|---|---|
| Annual equity retainer | $255,500 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $908,750 |
| Equity awards (grant-date value) | $1,277,138 |
| All other compensation | $0 |
| Total cost of the board | $2,185,888 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Charles River Laboratories International, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Charles River Laboratories International, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | Eli Lilly and Company | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 3 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 4 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 5 | IQVIA Holdings Inc. | 2025 | Ari Bousbib | 1,800,000 | 15,749,957 | 4,528,317 | 4,966,127 | 28,128,245 |
| 6 | Pfizer Inc. | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 7 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 8 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 9 | Medtronic, Inc. | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 10 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 11 | Merck & Co., Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 12 | Jazz Pharmaceuticals Public Company Limited | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 13 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 14 | Hologic Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 15 | Quest Diagnostics Incorporated | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 16 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 17 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 18 | Revvity | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 19 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 20 | Fortrea Holdings, Inc. | 2025 | Anshul Thakral | 401,923 | 10,479,169 | 0 | 687,500 | 11,584,483 |
| 21 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 22 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 23 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 24 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
| 25 | Mettler Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 26 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 27 | Catalent, Inc. | 2023 | Alessandro Maselli | 925,000 | 3,850,216 | 1,650,019 | 0 | 6,583,672 |
| 28 | Avantor, Inc. | 2025 | Emmanuel Ligner | 379,297 | 2,499,990 | 2,499,998 | 330,038 | 5,895,624 |
| 29 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 30 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| — | Icon plc | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Avantor, Inc. | 56.9% | PSU 50 · Options 25 · RSU 25 | Yes — TSR Relative to Comparator Group | FW Cook |
| Baxter International Inc. | not disclosed | PSU 50 · Stock Options 25 · RSU 25 | not disclosed | Aon |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Catalent, Inc. | 0% | PSU 50 · Options 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Fortrea Holdings, Inc. | 68.5% | PSU 50 · RSU 50 | No | Pay Governance LLC |
| Gilead Sciences, Inc. | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Hologic Inc. | 109% | PSU 50 · RSU 25 · Options 25 | No | not disclosed |
| Icon plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| IQVIA Holdings Inc. | not disclosed | PSU 75 · Options 25 | Yes | Meridian Compensation Partners, LLC |
| Jazz Pharmaceuticals Public Company Limited | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Medtronic, Inc. | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Merck & Co., Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Mettler Toledo International Inc. | 80% | PSU 33 · RSU 33 · Options 33 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners (PM&P) |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer |
| Pfizer Inc. | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
| Quest Diagnostics Incorporated | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSA 40 | not disclosed | Pay Governance LLC |
| Revvity | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, James Foster | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Summary Compensation Table”. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 2 | Section 01, Birgit Girshick | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Summary Compensation Table”. As printed: 5,898,392. Filing ↗machine: r6 · c53 · span 1145570–1145579 |
| 3 | Section 01, Joseph LaPlume | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Summary Compensation Table”. As printed: 3,513,345. Filing ↗machine: r9 · c53 · span 1161004–1161013 |
| 4 | Section 01, Victoria Creamer | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Summary Compensation Table”. As printed: 3,332,387. Filing ↗machine: r12 · c53 · span 1176439–1176448 |
| 5 | Section 01, Michael Knell | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Summary Compensation Table”. As printed: 2,107,684. Filing ↗machine: r4 · c53 · span 1135139–1135148 |
| 6 | Section 03, Joseph LaPlume PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r13 · c81 · span 1334714–1334721 |
| 7 | Section 03, Birgit Girshick PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r11 · c81 · span 1316537–1316546 |
| 8 | Section 03, Victoria Creamer RSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Grants of Plan Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r15 · c43 · span 1350840–1350847 |
| 9 | Section 03, James Foster PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r4 · c81 · span 1250260–1250269 |
| 10 | Section 03, Michael Knell PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r8 · c81 · span 1287582–1287589 |
| 11 | Section 03, Joseph LaPlume PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r14 · c81 · span 1345413–1345422 |
| 12 | Section 03, James Foster PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r3 · c81 · span 1239532–1239541 |
| 13 | Section 03, Joseph LaPlume RSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Grants of Plan Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r12 · c43 · span 1321937–1321944 |
| 14 | Section 03, Michael Knell RSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r7 · c81 · span 1276885–1276892 |
| 15 | Section 03, Birgit Girshick PSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r10 · c81 · span 1305811–1305820 |
| 16 | Section 03, Michael Knell RSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r6 · c81 · span 1268439–1268446 |
| 17 | Section 03, Birgit Girshick RSU | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “2025 Grants of Plan Based Awards” · grants of plan-based awards table. Filing ↗machine: t35 · r9 · c43 · span 1293006–1293015 |
| 18 | Section 07, pay ratio | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “CEO Pay Ratio”. As printed: 251 : 1. Filing ↗machine: span 1985635–1985638 |
| 19 | Section 08, Martin Mackay | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 365,859. Filing ↗machine: t17 · r1 · c29 · span 480113–480120 |
| 20 | Section 08, Virginia M. Wilson | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 345,859. Filing ↗machine: t17 · r2 · c29 · span 483215–483222 |
| 21 | Section 08, Paul Graves | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 345,708. Filing ↗machine: t17 · r3 · c29 · span 486335–486342 |
| 22 | Section 08, Reshema Kemps-Polanco | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r5 · c29 · span 492568–492575 |
| 23 | Section 08, Nancy C. Andrews | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r4 · c29 · span 489435–489442 |
| 24 | Section 08, Craig B. Thompson | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 340,859. Filing ↗machine: t17 · r6 · c29 · span 495669–495676 |
| 25 | Section 08, George Llado, Sr | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 325,859. Filing ↗machine: t17 · r7 · c29 · span 498794–498801 |
| 26 | Section 08, Mark Enyedy | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t18 · r1 · c29 · span 512947–512954 |
| 27 | Section 08, Abraham Ceesay | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t17 · r9 · c29 · span 505012–505019 |
| 28 | Section 08, Steven Barg | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 320,708. Filing ↗machine: t17 · r8 · c29 · span 501889–501896 |
| 29 | Section 08, George E. Massaro | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 28,750. Filing ↗ |
| 30 | Section 08, Richard F. Wallman | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 26,250. Filing ↗ |
| 31 | Section 08, Robert Bertolini | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 22,500. Filing ↗ |
| 32 | Section 08, Deborah T. Kochevar | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 21,250. Filing ↗ |
| 33 | Section 08, James C. Foster | DEF 14A | 2026-03-31 | 0001104659-26-037367 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Glenn Coleman 2026-05-01 | Form 4 | 2026-05-04 | 0001100682-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Steven Barg 2026-05-08 | Form 4 | 2026-05-12 | 0001100682-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Reshema Kemps-Polanco 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Craig B. Thompson 2026-05-08 | Form 4 | 2026-05-12 | 0001100682-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Paul Graves 2026-05-08 | Form 4 | 2026-05-12 | 0001100682-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Nancy C. Andrews 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000057 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, George Llado, Sr 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, James C. Foster 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, James C. Foster 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Virginia M. Wilson 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Reshema Kemps-Polanco 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Mark Enyedy 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Abraham Ceesay 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Martin Mackay 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, George Llado, Sr 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Martin Mackay 2026-05-08 | Form 4 | 2026-05-11 | 0001100682-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Nancy C. Andrews 2026-05-12 | Form 4 | 2026-05-14 | 0001100682-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Nancy C. Andrews 2026-05-12 | Form 4 | 2026-05-14 | 0001100682-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Michael Knell 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Victoria Creamer 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Birgit Girshick 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Victoria Creamer 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mark Mintz 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Mark Mintz 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Birgit Girshick 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Joseph LaPlume 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Joseph LaPlume 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michael Knell 2026-05-26 | Form 4 | 2026-05-28 | 0001100682-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Joseph LaPlume 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Mark Mintz 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Birgit Girshick 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Glenn Coleman 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Mark Mintz 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michael Knell 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Michael Knell 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Michael Knell 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Victoria Creamer 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Shannon M. Parisotto 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Joseph LaPlume 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Birgit Girshick 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Shannon M. Parisotto 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Victoria Creamer 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Shannon M. Parisotto 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Mark Mintz 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Victoria Creamer 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Joseph LaPlume 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Birgit Girshick 2026-05-29 | Form 4 | 2026-06-02 | 0001100682-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, James C. Foster 2026-05-30 | Form 4 | 2026-06-02 | 0001100682-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Steven Barg 2026-06-02 | Form 4 | 2026-06-03 | 0001100682-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Shannon M. Parisotto 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Birgit Girshick 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, James C. Foster 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Birgit Girshick 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Shannon M. Parisotto 2026-06-05 | Form 4 | 2026-06-08 | 0001100682-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, James C. Foster 2026-06-29 | Form 4 | 2026-07-01 | 0001100682-26-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 06, 2026 vote | Form 8-K | 2026-05-05 | 0000950103-26-007060 | Item 5.07 · say-on-pay result. As reported: 93.84% (votes for as printed: 41,356,139). Filing ↗ |
| 95 | Section 06, 2025 vote | Form 8-K | 2025-05-23 | 0001100682-25-000023 | Item 5.07 · say-on-pay result. As reported: 96.56% (votes for as printed: 40,218,870). Filing ↗ |
| 96 | Section 06, 2024 vote | Form 8-K | 2024-05-10 | 0001100682-24-000020 | Item 5.07 · say-on-pay result. As reported: 95.02% (votes for as printed: 43,833,503). Filing ↗ |
| 97 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 98 | Section 09b board cost (computed) | Computed | — | computed | Cash 908,750 + equity 1,277,138 + all other 0 = 2,185,888, summed across the director compensation table rows.machine: formula: Σ = 2,185,888 |
| 99 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 100 | Eli Lilly and Company, Section 10b CEO total | DEF 14A | 2026-03-20 | 0000059478-26-000029 | CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024 |
| 101 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 102 | Gilead Sciences, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 103 | IQVIA Holdings Inc., Section 10b CEO total | DEF 14A | 2026-02-27 | 0001628280-26-012892 | CEO total compensation as printed in IQVIA Holdings Inc.'s own proxy. As printed: 28,128,245. Filing ↗machine: t232 · r4 · c10 · span 1613956–1613966 |
| 104 | Pfizer Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0000078003-26-000033 | CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835 |
| 105 | Amgen Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145588 | CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166 |
| 106 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 107 | Medtronic, Inc., Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic, Inc.'s own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 108 | Bristol-Myers Squibb Company, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000014272-26-000006 | CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170 |
| 109 | Merck & Co., Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-147704 | CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022 |
| 110 | Jazz Pharmaceuticals Public Company Limited, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals Public Company Limited's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 111 | Becton, Dickinson and Company, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 112 | Hologic Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 113 | Quest Diagnostics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 114 | Charles River Laboratories International, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 115 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 116 | Revvity, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity's own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295 |
| 117 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 118 | Fortrea Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-178733 | CEO total compensation as printed in Fortrea Holdings, Inc.'s own proxy. As printed: 11,584,483. Filing ↗machine: t114 · r4 · c39 · span 498934–498944 |
| 119 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 120 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 121 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 122 | Regeneron Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 123 | Mettler Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 124 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 125 | Catalent, Inc., Section 10b CEO total | DEF 14A | 2023-12-15 | 0001193125-23-295996 | CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. Filing ↗machine: t161 · r3 · c31 · span 1055835–1055844 |
| 126 | Avantor, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001628280-26-021572 | CEO total compensation as printed in Avantor, Inc.'s own proxy. As printed: 5,895,624. Filing ↗machine: r3 · c9 · span 2130032–2130041 |
| 127 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997 |
| 128 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 129 | Section 10a, Amgen Inc. reciprocity | DEF 14A | — | 0001193125-26-145588 | Amgen Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 130 | Section 10a, Hologic Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 131 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 132 | Section 10a, Regeneron Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 133 | Section 10a, Merck & Co., Inc. reciprocity | DEF 14A | — | 0001193125-26-147704 | Merck & Co., Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 134 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc. names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 135 | Section 10a, Eli Lilly and Company reciprocity | DEF 14A | — | 0000059478-26-000029 | Eli Lilly and Company's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 136 | Section 10a, Fortrea Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-178733 | Fortrea Holdings, Inc. names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 137 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 138 | Section 10a, Pfizer Inc. reciprocity | DEF 14A | — | 0000078003-26-000033 | Pfizer Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 139 | Section 10a, Gilead Sciences, Inc. reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead Sciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 140 | Section 10a, Quest Diagnostics Incorporated reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Incorporated's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 141 | Section 10a, Revvity reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 142 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 143 | Section 10a, Avantor, Inc. reciprocity | DEF 14A | — | 0001628280-26-021572 | Avantor, Inc. names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 144 | Section 10a, Becton, Dickinson and Company reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 145 | Section 10a, IQVIA Holdings Inc. reciprocity | DEF 14A | — | 0001628280-26-012892 | IQVIA Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 146 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 147 | Section 10a, Jazz Pharmaceuticals Public Company Limited reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals Public Company Limited's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 148 | Section 10a, Bristol-Myers Squibb Company reciprocity | DEF 14A | — | 0000014272-26-000006 | Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 149 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names Charles River Laboratories International, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 150 | Section 10a, Mettler Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler Toledo International Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |
| 151 | Section 10a, Catalent, Inc. reciprocity | DEF 14A | — | 0001193125-23-295996 | Catalent, Inc.'s most recent proxy was read; its disclosed peer group does not include Charles River Laboratories International, Inc.. Filing ↗ |